Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DWC20151 and DWC20152 in Healthy Males
NCT02502721Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jun 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin and pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Peak Plasma Concentration and Area under the plasma concentration versus time curve. Started Jun 2015; status: completed.
02
Drugs
sitagliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02502721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502721.